The Lighthouse | 2012 December 21

Amarin “Hostile” Takeover

By Erik Zimerman On December 21, 2012 · 2 Comments · In The Whiskey Room

Background Amarin (AMRN) is an Irish based company with a recently FDA approved drug called Vascepa with very large market potential. Vascepa is broadly a prescription grade Omega 3 fatty acid (like those found in fish oils) based on highly purified EPA . Currently, the only other similar FDA approved drug comparable to Vascepa is Lovaza. Lovaza has reached annual sales of nearly $1 billion. Vascepa has several advantages over Lovaza, most importantly that it does not raise LDLs and in many cases lowers them. As far as market potential, Vascepa has a huge advantage over Lovaza. Lovaza was approved only for patients with very high triglycerides (>500 mg/dl) while Vascepa’s ANCHOR study shows that it is also effective for patients with high triglycerides (>200 mg/dl), and is on track to receive this label indication as well. The significance of this difference is hard to overstate. Lovaza’s prescription market population in the US is restricted to about 5 million Americans with very high triglycerides (which does not prevent it from selling $1 billion annually) while the US population with high triglycerides is 10 times that amount, at about 50 million. Though it should not be assumed that these two populations would purchase prescription drugs at the same rate, this fact alone makes [...]

[Continue Reading...]

S	M	T	W	T	F	S
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30	31

Amarin “Hostile” Takeover

Recent Posts

Top Posts & Pages

Halls

Archives

Subscribe to Blog via Email

Amarin “Hostile” Takeover

Recent Posts

Top Posts & Pages

Tags

Halls

Archives

Subscribe to Blog via Email